Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy

BACKGROUND: LDL cholesterol (LDLC) lowering has been revolutionized by PCSK9 inhibitors, Alirocumab (Praluent) and Evolocumab (Repatha), approved as adjuncts to maximally tolerated cholesterol lowering therapy in heterozygous (HeFH) or homozygous (HoFH) familial hypercholesterolemia, and/or clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Glueck, Charles J., Shah, Parth, Goldenberg, Naila, Prince, Marloe, Lee, Kevin, Jetty, Vybhav, Kumar, Ashwin, Goldenberg, Michael, Wang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788934/
https://www.ncbi.nlm.nih.gov/pubmed/26968977
http://dx.doi.org/10.1186/s12944-016-0227-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788934/
https://www.ncbi.nlm.nih.gov/pubmed/26968977
http://dx.doi.org/10.1186/s12944-016-0227-2

Ejemplares similares